You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on cancer immunotherapy.
New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.
The collaborations will evaluate whether patient-specific ex vivo cancer immunotherapy assays can predict in vivo efficacy, and ACEA's cell analysis platform.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
In a milestone for the cancer community, the agency approved Keytruda for the genomic features of a cancer, not where the tumor occurs in the body.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
A study demonstrated a connection between Epic's CTC-based PD-L1 assessment and patient outcomes, though clinical validation for immunotherapy prediction is still ongoing.
CSO Phil Stephens said the firm is finding specific genomic alterations that appear to affect sensitivity to immunotherapies, as it also advances overall mutation burden testing.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.